Clinical Trial Update: Belimumab Treatment of Emphysema Patients With Anti-GRP78 Autoantibodies [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating belimumab for emphysema patients with anti-GRP78 autoantibodies has completed; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease
• Emphysema

Drugs mentioned

• Belimumab (belimumab)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Chronic Obstructive Pulmonary Disease, Emphysema | Phase 2 | Status: COMPLETED | Results posted: 2023-07-18